Merck (MRK) Receivables - Net (2009 - 2026)
Merck's (MRK) quarterly Receivables - Net came in at $12.6 billion in Q2 2026, up 6.06% year-over-year from $11.8 billion in Q2 2025, and up 2.9% quarter-over-quarter from $12.2 billion in Q1 2026.
Analysis
Merck (MRK) Receivables - Net (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Receivables - Net for 18 consecutive years, with $12.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables - Net rose 6.06% year-over-year to $12.6 billion in Q2 2026; TTM through Jun 2026 was $12.6 billion, a 6.06% increase from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 14.57% from the prior year.
- Receivables - Net was $12.6 billion for Q2 2026 at Merck, up from $12.2 billion in the prior quarter.
- Over five years, Receivables - Net peaked at $12.6 billion in Q2 2026 and troughed at $9.5 billion in Q4 2022.
- A 5-year average of $10.9 billion and a median of $10.9 billion in 2023 frame the typical range for Receivables - Net.
- Across the five-year window, Receivables - Net rose 22.95% in 2022 and retreated 5.07% in 2025, its largest moves.
- Over 5 years, Receivables - Net stood at $9.5 billion in 2022, then rose by 9.51% to $10.3 billion in 2023, then dropped by 0.69% to $10.3 billion in 2024, then rose by 14.57% to $11.8 billion in 2025, then increased by 6.7% to $12.6 billion in 2026.
- The last three Receivables - Net figures came in at $12.6 billion (Q2 2026), $12.2 billion (Q1 2026), and $11.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.56 Bn |
| Mar 31, 2026 | 12.21 Bn |
| Dec 31, 2025 | 11.78 Bn |
| Sep 30, 2025 | 12.12 Bn |
| Jun 30, 2025 | 11.85 Bn |
| Mar 31, 2025 | 10.79 Bn |
| Dec 31, 2024 | 10.28 Bn |
| Sep 30, 2024 | 11.38 Bn |
| Jun 30, 2024 | 11.64 Bn |
| Mar 31, 2024 | 11.37 Bn |
| Dec 31, 2023 | 10.35 Bn |
| Sep 30, 2023 | 10.39 Bn |
| Jun 30, 2023 | 11.03 Bn |
| Mar 31, 2023 | 10.42 Bn |
| Dec 31, 2022 | 9.45 Bn |
| Sep 30, 2022 | 9.48 Bn |
| Jun 30, 2022 | 9.64 Bn |
| Mar 31, 2022 | 9.83 Bn |
| Dec 31, 2021 | 9.23 Bn |
| Sep 30, 2021 | 8.57 Bn |